Lifecore Biomedical, Inc. (LFCR)
(Delayed Data from NSDQ)
$4.72 USD
0.00 (0.00%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $4.73 +0.01 (0.21%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Balance Sheet
Fiscal Year End for Lifecore Biomedical, Inc falls in the month of May.
All items in Millions except Per Share data.
5/31/2024 | 5/31/2023 | 5/31/2022 | 5/31/2021 | 5/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 19 | 2 | 1 | 0 |
Receivables | NA | 29 | 48 | 70 | 76 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 41 | 67 | 70 | 66 |
Other Current Assets | NA | 5 | 7 | 7 | 14 |
Total Current Assets | NA | 94 | 124 | 148 | 157 |
Net Property & Equipment | NA | 134 | 130 | 180 | 192 |
Investments & Advances | NA | 0 | 0 | 45 | 57 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 18 | 29 | 106 | 107 |
Deposits & Other Assets | NA | 3 | 3 | 4 | 2 |
Total Assets | NA | 254 | 295 | 503 | 541 |
Liabilities & Shareholders Equity | 5/31/2024 | 5/31/2023 | 5/31/2022 | 5/31/2021 | 5/31/2020 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 22 | 16 | 48 | 52 |
Current Portion Long-Term Debt | NA | 1 | 41 | 29 | 89 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 11 | 17 | 20 | 19 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 4 | 1 | 1 | 0 |
Total Current Liabilities | NA | 39 | 79 | 102 | 164 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 6 | 14 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 166 | 98 | 165 | 101 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 3 | 0 | 4 | 5 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 218 | 187 | 300 | 310 |
Shareholders Equity | 5/31/2024 | 5/31/2023 | 5/31/2022 | 5/31/2021 | 5/31/2020 |
---|---|---|---|---|---|
Preferred Stock | NA | 39 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 174 | 167 | 166 | 163 |
Retained Earnings | NA | -179 | -59 | 39 | 71 |
Other Equity | NA | 0 | -1 | -1 | -3 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 35 | 108 | 203 | 231 |
Total Liabilities & Shareholder's Equity | NA | 254 | 295 | 503 | 541 |
Total Common Equity | 0 | -4 | 108 | 203 | 231 |
Shares Outstanding | 30.30 | 30.30 | 29.40 | 29.30 | 29.10 |
Book Value Per Share | 0.00 | -0.14 | 3.67 | 6.92 | 7.94 |
Fiscal Year End for Lifecore Biomedical, Inc falls in the month of May.
All items in Millions except Per Share data.
5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | -99,999 | 19 |
Receivables | NA | NA | NA | NA | 29 |
Notes Receivable | NA | NA | NA | NA | 0 |
Inventories | NA | NA | NA | NA | 41 |
Other Current Assets | NA | NA | NA | NA | 5 |
Total Current Assets | NA | NA | NA | NA | 94 |
Net Property & Equipment | NA | NA | NA | NA | 134 |
Investments & Advances | NA | NA | NA | NA | 0 |
Other Non-Current Assets | NA | NA | NA | NA | 0 |
Deferred Charges | NA | NA | NA | NA | 0 |
Intangibles | NA | NA | NA | NA | 18 |
Deposits & Other Assets | NA | NA | NA | NA | 3 |
Total Assets | NA | NA | NA | NA | 254 |
Liabilities & Shareholders Equity | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | NA | 0 |
Accounts Payable | NA | NA | NA | NA | 22 |
Current Portion Long-Term Debt | NA | NA | NA | NA | 1 |
Current Portion Capital Leases | NA | NA | NA | NA | 0 |
Accrued Expenses | NA | NA | NA | NA | 11 |
Income Taxes Payable | NA | NA | NA | NA | 0 |
Other Current Liabilities | NA | NA | NA | NA | 4 |
Total Current Liabilities | NA | NA | NA | NA | 39 |
Mortgages | NA | NA | NA | NA | 0 |
Deferred Taxes/Income | NA | NA | NA | NA | 0 |
Convertible Debt | NA | NA | NA | NA | 0 |
Long-Term Debt | NA | NA | NA | NA | 166 |
Non-Current Capital Leases | NA | NA | NA | NA | 0 |
Other Non-Current Liabilities | NA | NA | NA | 3 | |
Minority Interest (Liabilities) | NA | NA | NA | NA | 0 |
Total Liabilities | NA | NA | NA | NA | 218 |
Shareholders Equity | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | NA | 39 |
Common Stock (Par) | NA | NA | NA | NA | 0 |
Capital Surplus | NA | NA | NA | NA | 174 |
Retained Earnings | NA | NA | NA | NA | -179 |
Other Equity | NA | NA | NA | NA | 0 |
Treasury Stock | NA | NA | NA | NA | 0 |
Total Shareholder's Equity | NA | NA | NA | NA | 35 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | NA | 254 |
Total Common Equity | 0 | 0 | 0 | 0 | -4 |
Shares Outstanding | 30.30 | 30.30 | 30.30 | 30.30 | 30.30 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 |